Abstract
Whole blood filtration, mean erythrocyte aggregation, and erythrocyte membrane fluidity were examined in 10 patients with vascular atherosclerotic disease (VAD) and in 15 VAD patients with noninsulin-dependent diabetes mellitus (NIDDM) treated with mesoglycan (100 mg orally twice a day) for 30 days. The red cell membrane transverse fluidity gradient was evaluated in the VAD subjects, and the red cell membrane protein lateral mobility was measured in the VAD subjects with NIDDM. In both groups, mesoglycan treatment was responsible for an increase in erythrocyte membrane fluidity. This finding, which reflects an improvement in the dynamic properties of red cell membrane, assumes particular significance because this microrheologic parameter is always altered in VAD subjects, with or without NIDDM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
